Table 2.
Prevalence of positive subjects, broken down by gender and cohort: vaccine-eligible cohort (born between 1997 and 2001), pre-screening cohort (born between 1991 and 1996) and screening cohort (born before 1990). A significant p-values are indicated in bold (significance considered p < 0.05).
| Cohort | Males | Females | Total | ||||
|---|---|---|---|---|---|---|---|
| HPV-DNA+/N (%) | 95% CI | HPV-DNA+/N (%) | 95% CI | p | HPV-DNA+/N (%) |
95% CI | |
| Vaccine-eligible | 0/22 | 0.0–12.73 | 6/26 (23.08) | 9.92–41.95 | 0.01876 | 6/48 (12.50) | 5.86–24.70 |
| Pre-Screening | 7/57 (12.28) | 5.53–22.79 | 36/158 (22.78) | 16.75–29.81 | 0.08748 | 43/215 (20.0) | 15.06–24.19 |
| Screening | 12/61 (19.67) | 11.12–31.05 | 14/69 (20.29) | 12.04–30.99 | 0.9338 | 26/130 (20.0) | 13.79–27.53 |
| Total | 19/140 (13.57) | 8.62–20.01 | 56/253 (22.13) | 17.34–27.56 | 0.03729 | 75/393 (19.08) | 15.43–23.2 |